Literature DB >> 26690657

Emerging strategies for managing differentiated thyroid cancers refractory to radioiodine.

Stefania Bulotta1, Marilena Celano1, Giuseppe Costante1,2, Diego Russo3.   

Abstract

Efficient treatment of radio refractory thyroid cancer is still a major challenge. The recent identification of genetic and epigenetic alterations present in almost all differentiated tumors has revealed novel molecular targets, which can hopefully be exploited to create new treatments for these tumors. This review looks briefly at some of the innovative strategies currently being investigated for the treatment the radioiodine-resistant thyroid cancers.

Entities:  

Keywords:  Differentiated thyroid cancer; Molecular targets; Nanodevices; Radioiodine; Re-differentiation strategies

Mesh：

Substances：

Year:  2015        PMID： 26690657     DOI： 10.1007/s12020-015-0830-4

Source DB:  PubMed          Journal:  Endocrine        ISSN： 1355-008X            Impact factor:   3.633


  81 in total

1.  Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial.

Authors:  Marcia S Brose; Christopher M Nutting; Barbara Jarzab; Rossella Elisei; Salvatore Siena; Lars Bastholt; Christelle de la Fouchardiere; Furio Pacini; Ralf Paschke; Young Kee Shong; Steven I Sherman; Johannes W A Smit; John Chung; Christian Kappeler; Carol Peña; István Molnár; Martin J Schlumberger
Journal:  Lancet       Date:  2014-04-24       Impact factor: 79.321

Review 2.  Therapy of endocrine disease: response and toxicity of small-molecule tyrosine kinase inhibitors in patients with thyroid carcinoma: a systematic review and meta-analysis.

Authors:  E N Klein Hesselink; D Steenvoorden; E Kapiteijn; E P Corssmit; A N A van der Horst-Schrivers; J D Lefrandt; T P Links; O M Dekkers
Journal:  Eur J Endocrinol       Date:  2015-01-08       Impact factor: 6.664

3.  Integrated genomic characterization of papillary thyroid carcinoma.

Authors: 
Journal:  Cell       Date:  2014-10-23       Impact factor: 41.582

4.  A novel dual AMPK activator/mTOR inhibitor inhibits thyroid cancer cell growth.

Authors:  Robert L Plews; Adlina Mohd Yusof; Chaojie Wang; Motoyasu Saji; Xiaoli Zhang; Ching-Shih Chen; Matthew D Ringel; John E Phay
Journal:  J Clin Endocrinol Metab       Date:  2015-02-24       Impact factor: 5.958

Review 5.  The sodium iodide symporter (NIS): regulation and approaches to targeting for cancer therapeutics.

Authors:  Takahiko Kogai; Gregory A Brent
Journal:  Pharmacol Ther       Date:  2012-06-29       Impact factor: 12.310

6.  Lenvatinib versus placebo in radioiodine-refractory thyroid cancer.

Authors:  Martin Schlumberger; Makoto Tahara; Lori J Wirth; Bruce Robinson; Marcia S Brose; Rossella Elisei; Mouhammed Amir Habra; Kate Newbold; Manisha H Shah; Ana O Hoff; Andrew G Gianoukakis; Naomi Kiyota; Matthew H Taylor; Sung-Bae Kim; Monika K Krzyzanowska; Corina E Dutcus; Begoña de las Heras; Junming Zhu; Steven I Sherman
Journal:  N Engl J Med       Date:  2015-02-12       Impact factor: 91.245

7.  Sorafenib in the treatment of thyroid cancer.

Authors:  Silvia Martina Ferrari; Ugo Politti; Roberto Spisni; Gabriele Materazzi; Enke Baldini; Salvatore Ulisse; Paolo Miccoli; Alessandro Antonelli; Poupak Fallahi
Journal:  Expert Rev Anticancer Ther       Date:  2015-07-07       Impact factor: 4.512

8.  Challenging dogma in thyroid cancer molecular genetics--role of RET/PTC and BRAF in tumor initiation.

Authors:  James A Fagin
Journal:  J Clin Endocrinol Metab       Date:  2004-09       Impact factor: 5.958

Review 9.  The sodium/iodide symporter: state of the art of its molecular characterization.

Authors:  Elisabeth Darrouzet; Sabine Lindenthal; Didier Marcellin; Jean-Luc Pellequer; Thierry Pourcher
Journal:  Biochim Biophys Acta       Date:  2013-08-27

10.  Cytotoxic effects of a novel pyrazolopyrimidine derivative entrapped in liposomes in anaplastic thyroid cancer cells in vitro and in xenograft tumors in vivo.

Authors:  M Celano; S Schenone; D Cosco; M Navarra; E Puxeddu; L Racanicchi; C Brullo; E Varano; S Alcaro; E Ferretti; G Botta; S Filetti; M Fresta; M Botta; D Russo
Journal:  Endocr Relat Cancer       Date:  2008-06       Impact factor: 5.678
View more
  14 in total

Review 1.  Phytochemicals in thyroid cancer: analysis of the preclinical studies.

Authors:  Stefania Bulotta; Francesca Capriglione; Marilena Celano; Valeria Pecce; Diego Russo; Valentina Maggisano
Journal:  Endocrine       Date:  2021-02-15       Impact factor: 3.633

2.  Expression of YAP1 in aggressive thyroid cancer.

Authors:  Marilena Celano; Chiara Mignogna; Francesca Rosignolo; Marialuisa Sponziello; Michelangelo Iannone; Saverio Massimo Lepore; Giovanni Enrico Lombardo; Valentina Maggisano; Antonella Verrienti; Stefania Bulotta; Cosimo Durante; Carla Di Loreto; Giuseppe Damante; Diego Russo
Journal:  Endocrine       Date:  2017-01-24       Impact factor: 3.633

3.  Preliminary data of VEGF-A and VEGFR-2 polymorphisms as predictive factors of radiological response and clinical outcome in iodine-refractory differentiated thyroid cancer treated with sorafenib.

Authors:  Vincenzo Marotta; Concetta Sciammarella; Mario Capasso; Alessandro Testori; Claudia Pivonello; Maria Grazia Chiofalo; Rosario Pivonello; Luciano Pezzullo; Gerardo Botti; Annamaria Colao; Antongiulio Faggiano
Journal:  Endocrine       Date:  2016-12-16       Impact factor: 3.633

4.  BRAFV600E-mutant cancers display a variety of networks by SWIM analysis: prediction of vemurafenib clinical response.

Authors:  Rosa Falcone; Federica Conte; Giulia Fiscon; Valeria Pecce; Marialuisa Sponziello; Cosimo Durante; Lorenzo Farina; Sebastiano Filetti; Paola Paci; Antonella Verrienti
Journal:  Endocrine       Date:  2019-03-08       Impact factor: 3.633

5.  Quercetin improves the effects of sorafenib on growth and migration of thyroid cancer cells.

Authors:  Marilena Celano; Valentina Maggisano; Stefania Bulotta; Lorenzo Allegri; Valeria Pecce; Luana Abballe; Giuseppe Damante; Diego Russo
Journal:  Endocrine       Date:  2019-11-27       Impact factor: 3.633

6.  Synergistic cytotoxicity of the dipeptidyl peptidase-IV inhibitor gemigliptin with metformin in thyroid carcinoma cells.

Authors:  Si Hyoung Kim; Jun Goo Kang; Chul Sik Kim; Sung-Hee Ihm; Moon Gi Choi; Hyung Joon Yoo; Seong Jin Lee
Journal:  Endocrine       Date:  2017-12-28       Impact factor: 3.633

7.  Effects of nutraceuticals on anaplastic thyroid cancer cells.

Authors:  Lorenzo Allegri; Francesca Rosignolo; Catia Mio; Sebastiano Filetti; Federica Baldan; Giuseppe Damante
Journal:  J Cancer Res Clin Oncol       Date:  2017-12-02       Impact factor: 4.553

8.  Human telomerase reverse transcriptase in papillary thyroid cancer: gene expression, effects of silencing and regulation by BET inhibitors in thyroid cancer cells.

Authors:  Valentina Maggisano; Marilena Celano; Saverio Massimo Lepore; Marialuisa Sponziello; Francesca Rosignolo; Valeria Pecce; Antonella Verrienti; Federica Baldan; Catia Mio; Lorenzo Allegri; Marianna Maranghi; Rosa Falcone; Giuseppe Damante; Diego Russo; Stefania Bulotta
Journal:  Endocrine       Date:  2019-01-19       Impact factor: 3.633

9.  HER2 Analysis in Sporadic Thyroid Cancer of Follicular Cell Origin.

Authors:  Rosaria M Ruggeri; Alfredo Campennì; Giuseppe Giuffrè; Luca Giovanella; Massimiliano Siracusa; Angela Simone; Giovanni Branca; Rosa Scarfì; Francesco Trimarchi; Antonio Ieni; Giovanni Tuccari
Journal:  Int J Mol Sci       Date:  2016-12-06       Impact factor: 5.923

10.  Identification of tumorigenesis-related mRNAs associated with RNA-binding protein HuR in thyroid cancer cells.

Authors:  Federica Baldan; Catia Mio; Lorenzo Allegri; Ketty Conzatti; Barbara Toffoletto; Cinzia Puppin; Slobodanka Radovic; Carlo Vascotto; Diego Russo; Carla Di Loreto; Giuseppe Damante
Journal:  Oncotarget       Date:  2016-09-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.